News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
News Conference News AHA 2017 ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 Michael O'Riordan November 15, 2017
Presentation AHA 2017 Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial Presenter: Andre Lamy November 15, 2017
News Conference News AHA 2017 Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery Shelley Wood November 14, 2017
News Conference News AHA 2017 GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS Yael L. Maxwell November 14, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News AHA 2014 DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation Yael L. Maxwell November 16, 2014